Enhanced Self-Replicating Cell Selective Gene Delivery Systems

Improved gene delivery compositions, methods, and uses for targeted therapy in self-replicating cells, overcoming limitations of existing approaches.

Despite advances in gene therapy, existing self-replicating cell selective gene delivery compositions suffer from inefficient targeting, limited protein expression, and inadequate safety profiles. The original patent addressed some of these limitations, but there remains a need for further enhancements to improve efficacy, efficiency, and safety.

The new inventive concept introduces a system for delivering gene therapy to self-replicating cells, comprising a polyribonucleotide with a modified RNA molecule of interest and a microRNA target sequence, along with a delivery mechanism for selective targeting. Additionally, the concept includes methods for enhancing gene delivery, compositions for gene therapy, and systems for real-time monitoring and improving efficiency. These enhancements address the limitations of the original patent by providing more effective, safer, and more efficient gene delivery to self-replicating cells.

The new claims introduce novel modifications to the polyribonucleotide, such as the use of Venezuelan Equine Encephalitis viral replicase, circular polyribonucleotides, and liposome-based delivery mechanisms, which provide a non-obvious solution to the problems of inefficient targeting and limited protein expression.

Alternative embodiments may include the use of different viral replicases, modified RNA molecules, or alternative delivery mechanisms, such as nanoparticles or viral vectors. Variations may also include the incorporation of additional nonstructural viral proteins or the use of different microRNA target sequences.

The enhanced self-replicating cell selective gene delivery systems have significant commercial potential in the gene therapy market, particularly in the treatment of cancer, genetic disorders, and other diseases. The targeted and efficient delivery of gene therapy to self-replicating cells can provide a competitive advantage in the market, with potential applications in pharmaceutical, biotechnology, and research industries.